241 related articles for article (PubMed ID: 24395800)
1. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.
Lui VW; Peyser ND; Ng PK; Hritz J; Zeng Y; Lu Y; Li H; Wang L; Gilbert BR; General IJ; Bahar I; Ju Z; Wang Z; Pendleton KP; Xiao X; Du Y; Vries JK; Hammerman PS; Garraway LA; Mills GB; Johnson DE; Grandis JR
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1114-9. PubMed ID: 24395800
[TBL] [Abstract][Full Text] [Related]
2. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
Peyser ND; Freilino M; Wang L; Zeng Y; Li H; Johnson DE; Grandis JR
Oncogene; 2016 Mar; 35(9):1163-9. PubMed ID: 25982282
[TBL] [Abstract][Full Text] [Related]
3. PTPRT epigenetic silencing defines lung cancer with STAT3 activation and can direct STAT3 targeted therapies.
Sen M; Kindsfather A; Danilova L; Zhang F; Colombo R; LaPorte MG; Kurland BF; Huryn DM; Wipf P; Herman JG
Epigenetics; 2020; 15(6-7):604-617. PubMed ID: 31595832
[TBL] [Abstract][Full Text] [Related]
4. STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.
Peyser ND; Wang L; Zeng Y; Acquafondata M; Freilino M; Li H; Sen M; Gooding WE; Satake M; Wang Z; Johnson DE; Grandis JR
Cancer Prev Res (Phila); 2016 Aug; 9(8):657-63. PubMed ID: 27267892
[TBL] [Abstract][Full Text] [Related]
5. Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Peyser ND; Du Y; Li H; Lui V; Xiao X; Chan TA; Grandis JR
PLoS One; 2015; 10(8):e0135750. PubMed ID: 26267899
[TBL] [Abstract][Full Text] [Related]
6. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T.
Zhang X; Guo A; Yu J; Possemato A; Chen Y; Zheng W; Polakiewicz RD; Kinzler KW; Vogelstein B; Velculescu VE; Wang ZJ
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4060-4. PubMed ID: 17360477
[TBL] [Abstract][Full Text] [Related]
7. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.
Geiger JL; Grandis JR; Bauman JE
Oral Oncol; 2016 May; 56():84-92. PubMed ID: 26733183
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Veeriah S; Brennan C; Meng S; Singh B; Fagin JA; Solit DB; Paty PB; Rohle D; Vivanco I; Chmielecki J; Pao W; Ladanyi M; Gerald WL; Liau L; Cloughesy TC; Mischel PS; Sander C; Taylor B; Schultz N; Major J; Heguy A; Fang F; Mellinghoff IK; Chan TA
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9435-40. PubMed ID: 19478061
[TBL] [Abstract][Full Text] [Related]
9. Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.
Chen YW; Guo T; Shen L; Wong KY; Tao Q; Choi WW; Au-Yeung RK; Chan YP; Wong ML; Tang JC; Liu WP; Li GD; Shimizu N; Loong F; Tse E; Kwong YL; Srivastava G
Blood; 2015 Mar; 125(10):1589-600. PubMed ID: 25612622
[TBL] [Abstract][Full Text] [Related]
10. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas.
Lee TL; Yeh J; Friedman J; Yan B; Yang X; Yeh NT; Van Waes C; Chen Z
Int J Cancer; 2008 May; 122(9):1987-98. PubMed ID: 18172861
[TBL] [Abstract][Full Text] [Related]
11. Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer.
Peyser ND; Pendleton K; Gooding WE; Lui VW; Johnson DE; Grandis JR
PLoS One; 2016; 11(11):e0166185. PubMed ID: 27855189
[TBL] [Abstract][Full Text] [Related]
12. BMP10 suppresses hepatocellular carcinoma progression via PTPRS-STAT3 axis.
Yuan YM; Ma N; Zhang EB; Chen TW; Jiang H; Yin FF; Wang JJ; Zhang FK; Ni QZ; Wang X; Bao Y; Wang K; Cheng SQ; Zhang XL; Wang XF; Li JJ; Xie D
Oncogene; 2019 Nov; 38(48):7281-7293. PubMed ID: 31417183
[TBL] [Abstract][Full Text] [Related]
13. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Morris LG; Taylor BS; Bivona TG; Gong Y; Eng S; Brennan CW; Kaufman A; Kastenhuber ER; Banuchi VE; Singh B; Heguy A; Viale A; Mellinghoff IK; Huse J; Ganly I; Chan TA
Proc Natl Acad Sci U S A; 2011 Nov; 108(47):19024-9. PubMed ID: 22065749
[TBL] [Abstract][Full Text] [Related]
14. β1,6 GlcNAc branches-modified PTPRT attenuates its activity and promotes cell migration by STAT3 pathway.
Qi J; Li N; Fan K; Yin P; Zhao C; Li Z; Lin Y; Wang L; Zha X
PLoS One; 2014; 9(5):e98052. PubMed ID: 24846175
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
16. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Ortiz B; Fabius AW; Wu WH; Pedraza A; Brennan CW; Schultz N; Pitter KL; Bromberg JF; Huse JT; Holland EC; Chan TA
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8149-54. PubMed ID: 24843164
[TBL] [Abstract][Full Text] [Related]
17. Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T.
Zhao Y; Zhang X; Guda K; Lawrence E; Sun Q; Watanabe T; Iwakura Y; Asano M; Wei L; Yang Z; Zheng W; Dawson D; Willis J; Markowitz SD; Satake M; Wang Z
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2592-7. PubMed ID: 20133777
[TBL] [Abstract][Full Text] [Related]
18. The interaction of interleukin-8 and PTEN inactivation promotes the malignant progression of head and neck squamous cell carcinoma via the STAT3 pathway.
Xu Q; Ma H; Chang H; Feng Z; Zhang C; Yang X
Cell Death Dis; 2020 May; 11(5):405. PubMed ID: 32471980
[TBL] [Abstract][Full Text] [Related]
19. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma.
Li J; Shi C; Zhou R; Han Y; Xu S; Ma H; Zhang Z
Cancer Sci; 2020 Sep; 111(9):3222-3235. PubMed ID: 32589311
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system.
Sriuranpong V; Park JI; Amornphimoltham P; Patel V; Nelkin BD; Gutkind JS
Cancer Res; 2003 Jun; 63(11):2948-56. PubMed ID: 12782602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
